Citations (13)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
April N. Naegeli, Bridget L. Balkaran, Mingyang Shan, Theresa Marie Hunter, Lulu K. Lee & Vipul Jairath. (2022) The impact of symptom severity on the humanistic and economic burden of inflammatory bowel disease: a real-world data linkage study. Current Medical Research and Opinion 38:4, pages 541-551.
Read now
Read now
Articles from other publishers (12)
Isa Maria Steiner, Bernd Bokemeyer & Tom Stargardt. (2023) Mapping from SIBDQ to EQ-5D-5L for patients with inflammatory bowel disease. The European Journal of Health Economics 25:3, pages 539-548.
Crossref
Crossref
Gionata Fiorino, Nawal Bent-Ennakhil, Pasquale Varriale, Fiona Braegger & Eveline Hoefkens. (2024) Patient Preferences for Treatment Attributes in Inflammatory Bowel Disease: Results From a Large Survey Across Seven European Countries Using a Discrete Choice Experiment. Inflammatory Bowel Diseases.
Crossref
Crossref
Deborah A. Marshall, Karen V. MacDonald, Dina Kao, Charles N. Bernstein, Gilaad G. Kaplan, Humberto Jijon, Glen Hazlewood, Remo Panaccione, Yasmin Nasser, Maitreyi Raman & Paul Moayyedi. (2024) Patient preferences for active ulcerative colitis treatments and fecal microbiota transplantation. Therapeutic Advances in Chronic Disease 15.
Crossref
Crossref
Hassan Karami, Farbod Ebadi Fard Azar, Kamran Bagheri Lankarani, Aziz Rezapour, Sulmaz Ghahramani & Abdolvahab Baghbanian. (2023) Adalimumab versus Infliximab Treatment Outcome in Ulcerative Colitis: Application of EQ-5D, Visual Analogue Scale, and IBDQ-9 Measures: A Prospective Observational Study. Current Drug Safety 18:4, pages 484-495.
Crossref
Crossref
Ajit Sood, Arshdeep Singh, Ramit Mahajan, Vandana Midha, Charles N Bernstein & David T Rubin. (2023) (Re)Appraising Remission in Ulcerative Colitis. Inflammatory Bowel Diseases 29:8, pages 1317-1326.
Crossref
Crossref
Chanchal Kumar Ghosh, Sumona Islam, Nowrin Tabassum, Syed Arafat Mohiuddin, Md. Mosarrof Hossain, Aditi Sarkar & Amit Bari. (2023) Quality of Life of Patients With Inflammatory Bowel Disease in Bangladesh. Cureus.
Crossref
Crossref
Elizabeth Coates, Nyantara Wickramasekera, Amy Barr, Phil Shackley, Matthew Lee, Daniel Hind, Christopher Probert, Shaji Sebastian, Nikki Totton, Sue Blackwell, Hugh Bedford, Nicola Dames & Alan Lobo. (2022) Patient preferences and current practice for adults with steroid-resistant ulcerative colitis: POPSTER mixed-methods study. Health Technology Assessment 26:41, pages 1-118.
Crossref
Crossref
Yiyoung Kwon, Eun Sil Kim, Yon Ho Choe & Mi Jin Kim. (2022) How has the disease course of pediatric ulcerative colitis changed throughout the biologics era? A comparison with the IBSEN study. World Journal of Gastroenterology 28:28, pages 3666-3681.
Crossref
Crossref
Stefan Schubert, Nils Picker, Taner Cavlar, Jana Knop, Alisan Kahraman & Wolfgang Mohl. (2022) Inflammatory Bowel Disease Patients’ Treatment Preferences Using a Discrete Choice Experiment Technique: The InPuT Study. Advances in Therapy 39:6, pages 2889-2905.
Crossref
Crossref
Alex Al Khoury, Bhairavi Balram, Talat Bessissow, Waqqas Afif, Lorant Gonczi, Maria Abreu & Peter L. Lakatos. (2021) Patient Perspectives and Expectations in Inflammatory Bowel Disease: A Systematic Review. Digestive Diseases and Sciences 67:6, pages 1956-1974.
Crossref
Crossref
Carlos Taxonera, Daniel Carpio López, Ana Cabez Manas & Joaquin Ernesto Hinojosa del Val. (2022) Clinical settings with tofacitinib in ulcerative colitis. Revista Española de Enfermedades Digestivas.
Crossref
Crossref
Francisco Mesonero, Berta Juliá, Roberto SaldañaClaudia SaviniMercedes Cañas, Luis Cea-Calvo, Lidia Feo-Lucas, Sabela Fernández & Iago Rodríguez-Lago. (2020) Self-medication with oral corticosteroids reported by patients with ulcerative colitis: characteristics, reasons and patients’ behaviors. European Journal of Gastroenterology & Hepatology 33:4, pages 501-507.
Crossref
Crossref